Abstract
Objective: Understanding of other biological characteristics of Triple-negative breast cancer, the development of new therapeutical approaches and identification of new markers is necessary due to the lack of biological markers like ER, PR and HER2. The purpose of this study was to investigate the prognostic effect of the expression of aldehyde dehydrogenase-1 (ALDH1) in TNBC and its relationship with the clinico-pathological features Methods: In this study 87 patient files were searched for clinico-pathological data obtained from the files and paraffin blocks. The prognostic value of these clinical data and ALDH1 positivity were evaluated by determining disease-free survival. Results: TNM stage I vs III (p=0.03), vascular invasion (p=0.05), chemotherapy indication (p=0.02) were significantly associated with DFS. Multivariable analyses didn't demonstrate any statistically significant relationship between ALDH1 (p=0.61) and DFS. Conclusions: We didn\'t find any statistically significant relationship between ALDH1 positivity and DFS. There was no correlation between ALDH1 expression and tumor\'s pathological features .
Highlights
Triple-negative breast cancer is defined by absent expression of the estrogen receptor [ER], progesterone receptor [PR], and the human epidermal growth factor receptor 2 [HER2] negative status [1]
Given the lack of these biologic markers endocrine therapy and HER2-directed therapies are not recommended in the treatment of TNBC [1820]. the same general principles used in the diagnosis and treatment of non-triple-negative breast cancer generally apply to TNBC, it has a lot of differences in risk factors, molecular and histologic features, clinical behavior and chemotherapy sensitivity [2,3,4,5,6].TNBC defines a heterogeneous mix of breast tumors [7]
The prognostic value of these clinical data and aldehyde dehydrogenase-1 (ALDH1) positivity were evaluated by determining disease-free survival and tumor characteristics from the clinicopathological data obtained from the files and paraffin blocks
Summary
Triple-negative breast cancer is defined by absent expression of the estrogen receptor [ER], progesterone receptor [PR], and the human epidermal growth factor receptor 2 [HER2] negative status [1]. Given the lack of these biologic markers endocrine therapy and HER2-directed therapies are not recommended in the treatment of TNBC [1820]. the same general principles used in the diagnosis and treatment of non-triple-negative breast cancer generally apply to TNBC, it has a lot of differences in risk factors, molecular and histologic features, clinical behavior and chemotherapy sensitivity [2,3,4,5,6].TNBC defines a heterogeneous mix of breast tumors [7].
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
